Could self-disseminating vaccines cut off emerging infectious diseases at source?

November 01, 2015

The 2014/2015 Ebola outbreak in West Africa shone the spotlight not only on the unpreparedness of local health services and science to deal with the pandemic, but also on the phenomenon of emerging infectious diseases (EIDs).

In an expert review published online today (Monday 2nd November 2015) in Expert Review of Vaccines, Dr. Michael Jarvis (who is a molecular virologist from Plymouth University School of Biomedical Sciences and who is an expert in EIDs and the use of self-disseminating vaccines to control them) identifies self-disseminating vaccines as one potential way forward to deal with future pandemics with potential to cut off such diseases at the animal source before they spread to human populations.

It is the first time that self-disseminating vaccines have been the subject of such a review.

EIDs are an increasing risk to human health. Modern human activity has an irreversible effect on the natural world. Widespread global travel, the spread of agriculture into wildlife habitats, deforestation and urbanisation are bringing humans and wildlife into unprecedented proximity.

In most cases animals are the source of EIDs - Ebola, HIV, avian flu, Hendra, SARS, MERS and Marburg are a selection of such diseases which have spread to human populations from animals. Most EIDs were entirely unknown before they entered the human population.

The challenge, identified in the expert review, is to discover vaccines for these diseases and find ways in which to deliver those vaccines to target animal populations. Self-disseminating vaccines are designed to use virus-based vectors (cytomegalovirus (CMV) which are viruses that are unique to individual species but which have little or no significant impact on that species' health). The vectors in effect become 'carriers' for the vaccine which allow for vaccination across populations where it is difficult to inoculate every animal.

While not a new approach (the review states that a similar method was used to combat myxomatosis and rabbit haemorrhagic fever in European rabbit populations) its adoption has been comparatively slow with a recent acceleration in interest as the method became identified as a way to combat Ebola.

Dr. Jarvis was senior author of the review. He said: "In this review we have explored self-disseminating vaccines as an innovative means to prevent EID transmission from animals to humans. From HIV to Ebola and SARS, highly virulent pathogens are continually emerging from animals into the human population. Our review has been based on discussion with scientists from across the conventional and disseminating vaccine fields, and we have used the experience gained through my own and that of my co-author's experimental work. We suggest that state-of-the-art disseminating vaccines may have a role to play as a new and potentially powerful strategy to circumvent EID at the animal source before their establishment as the next human pandemic."
Expert Review of Vaccines
Self-disseminating vaccines for merging infectious diseases
Aisling A. Murphy, Alec J. Redwood, Michael A. Jarvis
DOI: 10.1586/14760584.2016.1106942

University of Plymouth

Related Ebola Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

Why doesn't Ebola cause disease in bats, as it does in people?
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people.

Ebola transmission risks would be taken more seriously with ground-up interventions
A study led by the University of Kent's Durrell Institute of Conservation and Ecology (DICE) has found significant differences in disease risk perception and channels of information about Ebola virus disease (EVD) in rural areas and urban centres of Guinea, West Africa.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.

Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.

Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.

Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.

How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.

Read More: Ebola News and Ebola Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to